anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
It is suitable for all newborns to observe and evaluate the sleep phase, wake period and regularity, and guide the choice of care time. The scale includes four dimensions: eye movement, breathing rate, facial expression and muscle activity. The score range of each dimension is 0 \~ 2 points, and the score range is 0 \~ 8 points.
The cDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in other vertebrate species. The genes encoding these NPs can be used to effect modifications of the sequence to produce alternate forms of the NPs and to provide practical amounts of these proteins. The NPs of the invention can also be synthesized chemically. The invention peptides have the formula:wherein R1 is selected from the group consisting of:or a 10- to 109-amino acid sequence shown as the native upstream sequence for porcine, canine or human BNP in FIG. 8, or a composite thereof;R2 is (OH), NH2, or NR'R'' wherein R' and R'' are independently lower alkyl (1-4C) or isand R1 is Asp-Ser-Gly-, R2 cannot be Asn-Val-Leu-Arg-Arg-Tyr.The peptides of the invention can be formulated into pharmaceutical compositions and used to treat conditions associated with high extracellular fluid levels, especially congestive heart failure.
BACKGROUND: Susceptibility to respiratory infections increases with age. Diagnosing and treating tuberculosis in the elderly comes with the challenges of fewer specific symptoms and possibly more side effects of treatment. Much is unknown when it comes to tuberculosis in the elderly, especially in relation to inflammation, which may impact mortality. We, therefore, investigated a clinical cohort of elderly tuberculosis patients.
METHODS: Patients aged ≥65 years, admitted to our tuberculosis reference center between 2005 and 2021, were retrospectively included in our cohort. Sociodemographic data, clinical characteristics, laboratory results, including inflammatory markers at baseline (monocyte, neutrophil, lymphocyte count, and CRP levels), and treatment outcomes were collected. They were compared to the National Dutch TB Registry and analyzed using descriptive statistics. Survival analysis was performed using univariate Cox regression analysis and a log-rank test. Results were visualized in Kaplan-Meier curves.
RESULTS: 104 elderly tuberculosis patients, mostly European, with a mean age of 75 years, were included. None were HIV-infected. Miliary tuberculosis cases were overrepresented (14 %) compared to the National Dutch TB Registry (5 % in elderly, 2 % adults). Fever occurred in 77 % (57/74), and the duration of fever decreased with age. Innate immune markers, including monocyte/lymphocyte-ratio, moderately correlated with CRP. Overall mortality was 15 %, and highest (33 %) in patients with CRP levels >100 mg/mL.
CONCLUSION: In elderly tuberculosis patients in a low-incidence setting, mortality rates are higher in comparison to younger patients. The overrepresentation of miliary tuberculosis may suggest waning immunity, with a subset of patients exhibiting strong inflammation associated with increased mortality.
PURPOSE: A composition containing niphimycin as an active ingredient for preventing pathogenic fungi in plants is provided to be used as an eco-friendly biocidal composition with high biodegradation and to prevent anthracnose in Capsicum annuum, thereby being used in industries for preventing plant diseases. CONSTITUTION: A composition for preventing pathogenic fungi in plants contains niphimycin as an active ingredient and prevents Colletotrichum coccodes. Streptomyces hygroscopicus subsp. enhygrus (deposit number KACC91654P) has an antibacterial activity against pathogenic fungi in plants. A method for preparing antibiotics with an antibacterial activity against pathogenic fungi in plants comprises the steps of: extracting a bacterial body or spores of Streptomyces hygroscopicus subsp. enhygrus, (deposit number KACC91654P), a mixture thereof, or a culture of the strain using butanol; and isolating and purifying niphimycin (chemical formula 1) from the butanol extract.
This invention relates to an immunological adjuvant. The immunological adjuvant is levomisole, or derivative thereof, or a composition consisting of levomisole or derivative thereof and at least one of while oil, glycerol, oleic acid, DDA or saponin. The immunological adjuvant of the present invention can effectively stimulate the immunological adjuvant of the present invention can effectively stimulate the immunological reaction capacity of protein vaccine, nucleic acid vaccine, polypeptide vaccine and inactivated vaccine. The immunological adjuvant also can enhance the immunological effect of T cell and extend protective period. The method for preparing the immunological adjuvant of the present invention is easy. The immunological adjuvant can be used widely and can bring enormous benefit.
The invention discloses external Chinese medicinal liquor for treating gout, acute coronary insufficiency, hypertension, chiral and pedal numbness and stremma, which consists of the following raw material medicaments: Chinese angelica, pilose asiabell root, safflower, helleborus thibetauns, fortune's drynaria rhizome, sappan wood, szechuan lovage rhizome, rehmannia glutinosa, twotooth achyranthes root and peach seed. A method for preparing the external Chinese medicinal liquor comprises the steps of: washing, drying and grinding the medicaments; putting the obtained product into a sterilized pot container; adding 50-degree white spirit into the pot container; covering a cover on the pot container for sealing; and soaking for 30 days at the room temperature to obtain the external Chinese medicinal liquor. The invention provides the external Chinese medicinal liquor, which can strengthen immunologic function in vivo, rapidly eliminate various arthritis, rheumatoid diseases, scapulohumeral periarthritis, chiral and pedal numbness, stremma and hypertension, rapidly relieve various fatigues and promote sleeping. The product is a purely natural product, has no toxic or side effects on the human body and has good curative effect. The patients with short medical history can be cured after using the external Chinese medicinal liquor for 3 to 4 courses of treatment and the patients with long medical history can be cured after using the external Chinese medicinal liquor for 8 to 15 courses of treatment. The statistics of the use of more than 250 patients shows that some patients are not relapsed until now after being cured, the total effective rate of the external Chinese medicinal liquor reaches over 95 percent and the cure rate of the external Chinese medicinal liquor reaches over 90 percent.
Patients randomized to PEA will undergo surgery within 4 months after randomization and optional run-in phase. Distality of the dissection plane is at the discretion of the operating physicians.
Background and Objectives: No studies have reported corrugator muscle activity associated with pain in people with pain. This study aimed to develop an objective pain assessment method using corrugator muscle activity with pressure pain stimulation to the skeletal muscle. Methods: Participants were 20 adults (a mean ± SD age of 22.0 ± 3.1 years) with chronic neck/shoulder pain. Surface electromyography (sEMG) of corrugator muscle activity at rest (baseline) and without and with pressure pain stimulation applied to the most painful tender point in the shoulder was recorded. Participants evaluated the intensity of the neck/shoulder pain and the sensory and affective components of pain with pressure stimulation using a visual analogue scale (VAS). The percentages of integrated sEMG (% corrugator activity) without and with pressure pain stimulation to the baseline integrated sEMG were compared, and the relationships between the % corrugator activity and the sensory and affective components of pain VAS scores were evaluated. Results: Without pressure stimulation, an increase in corrugator muscle activity due to chronic neck/shoulder pain was not observed. The % corrugator activity with pressure pain stimulation was significantly higher than that without stimulation (p < 0.01). A significant positive correlation between corrugator muscle activity and the affective components of pain VAS scores with pressure stimulation was found (ρ = 0.465, p = 0.039) and a tendency of positive correlation was found for the sensory component of pain VAS scores (ρ = 0.423, p = 0.063). Conclusions: The increase in corrugator muscle activity with pressure pain stimulation to the tender point in adults with chronic neck/shoulder pain was observed, although increased corrugator muscle activity resulting from the chronic neck/shoulder pain was not. These findings suggest that corrugator muscle activity with pressure pain stimulation can be a useful objective indication for tender point sensitivity assessment in the skeletal muscle with pain.
The minimal amount of air will be used during insertion to open the lumen. Minimal amounts of water (10 to 50 mL) at room temperature will be used for washing of residual feces. If insertion is hindered by scope looping, attempts at loop reduction will be made. If advancement does not occur within 3 to 5 minutes, an assistant will provide abdominal compression, followed by changing the patient's position to facilitate passage of the colonoscope. Cecal intubation will be suggested by identification of the appendiceal orifice and ileocecal valve or intubation of the terminal ileum.
This was an open-label randomized single institution pilot study to evaluate the safety and immunologic response to MAGE-A3 immunotherapeutic administered by either of two injection routes (i.m. or i.d./s.c.). Patients were studied following IRB approval (IRB #15398) and documentation of informed consent. The trial was registered in clinicaltrials.gov (NCT01425749), and was performed at the University of Virginia.

MAGE-A3 immunotherapeutic (0.5 ml) was administered five times (weeks 0, 3, 6, 9, 12) in extremities uninvolved with melanoma. Vaccines 1 and 3 were administered at the same site: other vaccine sites were rotated among available extremities. Subjects were randomized 1:1, within each stratum (AJCC stage II/III or IV), to i.m. (Group A) or i.d./s.c. (Group B) administration. The randomization code was generated by the study statistician using varying block sizes of 2 to 4. For group B patients, half of the dose was injected s.c., then the needle was withdrawn to the dermis, then advanced intradermally from that same puncture site and the remaining half dose was injected i.d. Immune responses were evaluated in a SIN and PBMC.
To investigate the role of co-stimulatory and co-inhibitory molecules on immune tolerance in immune thrombocytopenia (ITP), this study mapped the immune cell heterogeneity in the bone marrow of ITP at the single-cell level using Cytometry by Time of Flight (CyTOF). Thirty-six patients with ITP and nine healthy volunteers were enrolled in the study. As soluble immunomodulatory molecules, more sCD25 and sGalectin-9 were detected in ITP patients. On the cell surface, co-stimulatory molecules like ICOS and HVEM were observed to be upregulated in mainly central memory and effector T cells. In contrast, co-inhibitory molecules such as CTLA-4 were significantly reduced in Th1 and Th17 cell subsets. Taking a platelet count of 30×109 L-1 as the cutoff value, ITP patients with high and low platelet counts showed different T cell immune profiles. Antigen-presenting cells such as monocytes and B cells may regulate the activation of T cells through CTLA-4/CD86 and HVEM/BTLA interactions, respectively, and participate in the pathogenesis of ITP. In conclusion, the proteomic and soluble molecular profiles brought insight into the interaction and modulation of immune cells in the bone marrow of ITP. They may offer novel targets to develop personalized immunotherapies.
In kidney transplant recipients, non-adherence to immunosuppressant medications post-transplant has been associated with a range of negative implications, including increased healthcare utilization, rejection of the graft, kidney loss, and death. Specifically, adolescents and young adults are the most at risk populations for experiencing death-censored graft loss and medication non-adherence. Previous studies have reported rates of non-adherence in this population ranging from 50-70%, and even minor deviations in immunosuppressant medication adherence have been shown to have negative effects. The use of mobile health (mHealth) technology could prove useful in aiding transplant recipients to stay adherent to their medical regimen.

We will use a mobile health platform that enables users to track dose-by-dose medication adherence through asynchronous, video directly observed therapy (DOT). This helps patients take their medication as prescribed and gives providers the assurance that their patients are supported and successful in treatment. DOT is the practice of watching a patient take every dose of medicine in-person, and has typically only been done in extreme cases because it can be both costly and burdensome: DOT is the standard of care for Tuberculosis treatment and has proven high-adherence rates. Through mHealth technology, DOT can be used more broadly and without added burden; emocha's technology allows this through enabling patients to use their mobile application to view their regimen, record themselves taking every dose of their medication, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review. The aim of this study is to perform a pilot trial examining the rates of medication adherence in adolescent kidney transplant recipients who use a novel mHealth system, and to understand the acceptability/satisfaction with using this technology.
INTRODUCTION/AIMS: Not all patients with chronic inflammatory demyelinating polyneuropathy (CIDP) have evidence of demyelination on nerve conduction studies (NCS). Patients with "supportive" evidence of CIDP on cerebrospinal fluid (CSF), magnetic resonance imaging (MRI), ultrasound (US), or nerve biopsy but not on NCS, often receive immunomodulating therapy. We evaluated the treatment response of patients with clinical and supportive features of CIDP lacking NCS evidence of demyelination.
METHODS: Retrospective chart review was conducted on 232 patients who met CIDP clinical criteria and were treated with disease-modifying therapy. Patients included did not have NCS criteria of demyelination, but did have supportive CSF, MRI, or US findings consistent with CIDP. A positive treatment response was defined as at least a one-point improvement in the modified Rankin scale (mRS), or a four-point increase in the Medical Research Council sum score (MRCSS).
RESULTS: Twenty patients met criteria: 17 of the 18 (94%) patients with CSF protein >45 mg/dL, 6 of the 14 (43%) with MRI lumbosacral root or plexus enhancement, and 4 of the 6 (67%) with enlarged proximal nerves on US. Eighteen patients received intravenous immunoglobulin, 10 corticosteroids, one plasma exchange, and six other immunomodulatory therapies. Twelve patients had a positive treatment response on the MRCSS or mRS. The presence of MRI lumbosacral root or plexus enhancement was associated with a positive treatment response.
DISCUSSION: A trial of immunomodulating treatment should be considered for patients with clinical features of CIDP in the absence of NCS evidence of demyelination, particularly when there is MRI lumbosacral root or plexus enhancement.
Self-etching Dentine Bonding Agent. Scotchbond Universal by 3M ESPE. Topical application followed by light curing for 20 seconds.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: present invention refers to molecular biology, and can be used in neurology and endocrinology. A ligand-binding domain of a soluble corticotrophin release factor receptor type 2 (sCRFR2) which is characterised by an ability to inhibit said receptor activity in the presence of a ligand selected from a group including the corticotrophin release factor, urocortin-1, urocortin-2, urocortin-3 and stresscophin is produced. What is offered is using the produced sCRFR2 or its conjugate with polyethylene glycol as a CRFR2 activity modulator and/or a pharmacological effect of a bound ligand. ^ EFFECT: production of the new compositions. ^ 6 cl, 17 dwg, 2 tbl, 1 ex
The subjects in the study group will be applied NDT 20 minutes twice a week, each session lasting 40 minutes, and in addition, an eccentric exercise program of 20 minutes will be applied in each session. For eccentric exercise training, a functional eccentric exercise program will be applied especially for the hip flexor (m. iliopsoas, m. rectus femoris) muscle group, which is the most common and intense spasticity seen in the lower extremities, hip adductors (m. adductor magnus and minimus, m. adductor longus and brevia, m. pectineus, m. gracillis), knee flexors (m. semitendinosus, m. semimembranouzsu, m. biceps femoris) and plantar flexors (m. gastrocnemius, m. soleus and m. tibialis posterior). If the orthosis used by the individual is applied during the eccentric exercise program, it will be removed.
The present invention relates to traditional Chinese medicine for treating hyperostosis, cervical spondylosis and prolapse of lumbar intervertebral disc and a preparation method thereof. The present invention is characterized in that the weight composition of the medicine effect components is 12 to 16 shares of tortoise plastron, 12 to 16 shares of tribulus terrestris, 12 to 16 shares of avicennia pricklyash root, 12 to 16 shares of paniculate swallowwort root, 12 to 16 shares of hemp fruit, 12 to 16 shares of red peony root, 5 to 8 shares of arrowhead corm and 8 to 12 shares of aralia root. In the preparation process, firstly, the soft bark of aralia root is decocted with water, and concentrated liquid is prepared. Avicennia pricklyash root is placed in the prepared concentrated liquid to be soaked for one week and is stirred evenly with vinegar and dried by sauting, and avicennia pricklyash root is placed for one week; subsequently, avicennia pricklyash root is wet by spirit and is dried by sauting; other kinds of traditional Chinese medicine are all dried by sauting, and encapsulation is carried out after other kinds of traditional Chinese medicine are mixed and ground into powder and are sieved. The present invention has the functions of wind dispersion, damp elimination, cold removal, fever reduction, tendon relaxation, blood activation, bone promotion, clot absorption, stasis elimination and channel activation. The present invention has the advantages of good therapeutic effect, short course of treatment and no relapse, and the pain of operations for patients with lumbar intervertebral disc can be avoided.
Despite undeniable advances in modern medicine, lung cancer still has high morbidity and mortality rates. Lung cancer is preventable and treatable, and it is important to identify new risk factors for lung cancer, especially those that can be treated or reversed. Obstructive sleep apnea (OSA) is a very common sleep-breathing disorder that is grossly underestimated in clinical practice. It can cause, exacerbate, and worsen adverse outcomes, including death and various diseases, but its relationship with lung cancer is unclear. A possible causal relationship between OSA and the onset and progression of lung cancer has been established biologically. The pathophysiological processes associated with OSA, such as sleep fragmentation, intermittent hypoxia, and increased sympathetic nervous excitation, may affect normal neuroendocrine regulation, impair immune function (especially innate and cellular immunity), and ultimately contribute to the occurrence of lung cancer, accelerate progression, and induce treatment resistance. OSA may be a contributor to but a preventable cause of the progression of lung cancer. However, whether this effect exists independently of other risk factors is unclear. Therefore, by reviewing the literature on the epidemiology, pathogenesis, and treatment of lung cancer and OSA, we hope to understand the relationships between the two and promote the interdisciplinary exchange of ideas between basic medicine, clinical medicine, respiratory medicine, sleep medicine, and oncology.
Liver fibrosis is the excessive accumulation of extracellular matrix proteins that occurs in most types of chronic liver disease. At the cellular level, liver fibrosis is associated with the activation of hepatic stellate cells (HSCs) which transdifferentiate into a myofibroblast-like phenotype that is contractile, proliferative and profibrogenic. HSC transdifferentiation induces genome-wide changes in gene expression that enable the cell to adopt its profibrogenic functions. We have previously identified that the deubiquitinase ubiquitin C-terminal hydrolase 1 (UCHL1) is highly induced following HSC activation; however, the cellular targets of its deubiquitinating activity are poorly defined. Here, we describe a role for UCHL1 in regulating the levels and activity of hypoxia-inducible factor 1 (HIF1), an oxygen-sensitive transcription factor, during HSC activation and liver fibrosis. HIF1 is elevated during HSC activation and promotes the expression of profibrotic mediator HIF target genes. Increased HIF1α expression correlated with induction of UCHL1 mRNA and protein with HSC activation. Genetic deletion or chemical inhibition of UCHL1 impaired HIF activity through reduction of HIF1α levels. Furthermore, our mechanistic studies have shown that UCHL1 elevates HIF activity through specific cleavage of degradative ubiquitin chains, elevates levels of pro-fibrotic gene expression and increases proliferation rates. As we also show that UCHL1 inhibition blunts fibrogenesis in a pre-clinical 3D human liver slice model of fibrosis, these results demonstrate how small molecule inhibitors of DUBs can exert therapeutic effects through modulation of HIF transcription factors in liver disease. Furthermore, inhibition of HIF activity using UCHL1 inhibitors may represent a therapeutic opportunity with other HIF-related pathologies.
Assemblies in accordance with the invention can lead to an exceptionally easy to use, safe, and convenient system and method of applying a fixed dosage of chemicals to which a user might wish to avoid contact, such as parasiticides. In the present invention, a fluid, such as a pesticide or parasiticide, glue, solvent, lubricant, medicament and the like is loaded into a fluid reservoir and the reservoir sealed. The reservoir can be attached to a cap-applicator structure which is in an inactive configuration. In the inactive configuration, a piercing tip remains poised over the reservoir in an inactive configuration without forming an opening in the reservoir. The cap- applicator can have a sharp intsernal piercing tip capable of piercing the reservoir when the assembly is converted into an active configuration. This will allow the user to dispense the liquid out of the reservoir through the applicator.